文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

多黏菌素B血液灌流对严重脓毒症患者人类白细胞抗原DR表达的影响

The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients.
PubMed 文献 · Crit Care · 2018-10-26
一句话结论在血内毒素活性检测≥0.6的严重脓毒症患者中,多黏菌素B血液灌流可提高第3天较基线的单核细胞HLA-DR表达变化,但28天临床结局无差异。

该随机对照试验纳入血内毒素活性检测(EAA)≥0.6的严重脓毒症患者59例,随机分为多黏菌素B血液灌流(PMX-HP)组29例(连续2天、每天2小时PMX-HP加标准治疗)和非PMX-HP组30例(仅标准治疗)。主要终点为第3天较基线单核细胞HLA-DR表达变化的中位数,PMX-HP组高于标准治疗组(P=0.027);CD11b第3天较基线平均变化PMX-HP组显著低于非PMX-HP组(P=0.002)。中性粒细胞趋化、presepsin、心血管SOFA评分、血管升压药剂量、EAA水平组间无显著变化;第28天死亡率、无ICU天数、无呼吸机天数、透析依赖状态、肾功能恢复、血清肌酐、无血管升压药天数及MAKE 28组间相当。作者认为PMX-HP改善了严重脓毒症患者的mHLA-DR表达,未来研究应探讨PMX-HP在低mHLA-DR表达患者中的潜在获益。

要点

  • 纳入标准为血内毒素活性检测(EAA)≥0.6的严重脓毒症患者,PMX-HP组接受连续2天、每天2小时PMX-HP加标准治疗。
  • 主要终点第3天较基线mHLA-DR表达变化的中位数PMX-HP组高于非PMX-HP组(P=0.027)。
  • 第3天较基线CD11b平均变化PMX-HP组显著低于非PMX-HP组(P=0.002)。
  • 中性粒细胞趋化、presepsin、CVS SOFA评分、血管升压药剂量、EAA水平组间无显著变化。
  • 第28天死亡率、无ICU天数、无呼吸机天数、透析依赖、肾功能恢复、血清肌酐、无血管升压药天数及MAKE 28组间相当。

适用人群与场景

  • 严重脓毒症患者,血内毒素活性检测(EAA)水平≥0.6。

诊断标准与关键阈值

  • 纳入标准:血内毒素活性检测(EAA)水平≥0.6。

处置流程与药物剂量

  • PMX-HP组:接受2小时PMX-HP治疗加标准治疗,连续2天。
  • 非PMX-HP组:仅接受标准治疗。

研究设计与关键结果

  • 随机对照试验,共59例患者随机分为PMX-HP组(n=29)和非PMX-HP组(n=30)。
  • 基线时mHLA-DR表达、CD11b、中性粒细胞趋化及临床参数组间相当。
  • 主要终点:第3天较基线mHLA-DR表达变化的中位数PMX-HP组高于仅接受标准治疗组(P=0.027)。
  • 第3天较基线CD11b平均变化PMX-HP组显著低于非PMX-HP组(P=0.002)。
  • 中性粒细胞趋化、presepsin、CVS SOFA评分、血管升压药剂量、EAA水平从基线变化组间无显著差异。
  • 入组后第28天,死亡率、无ICU天数、无呼吸机天数、透析依赖状态、肾功能恢复、血清肌酐、无血管升压药天数及MAKE 28组间相当。

证据类型、等级与局限

  • 证据类型:随机对照试验。
  • 试验注册号:ClinicalTrials.gov NCT02413541,注册日期2015年3月3日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为PMX-HP改善了严重脓毒症患者的mHLA-DR表达。
  • 作者建议未来研究应探讨PMX-HP在低mHLA-DR表达患者中的潜在获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Recent randomized trials have not found that polymyxin B hemoperfusion (PMX-HP) improves outcomes for patients with sepsis. However, it remains unclear whether the therapy could provide benefit for highly selected patients. Monocyte human leukocyte antigen (mHLA-DR) expression, a critical step in the immune response, is decreased during sepsis and leads to worsening sepsis outcomes. One recent study found that PMX-HP increased mHLA-DR expression while another found that the treatment removed HLA-DR-positive cells.

METHODS: We conducted a randomized controlled trial in patients with blood endotoxin activity assay (EAA) level ≥ 0.6. Patients in the PMX-HP group received a 2-h PMX-HP treatment plus standard treatment for 2 consecutive days. Patients in the non-PMX-HP group received only standard treatment. The primary outcome compared the groups on median change in mHLA-DR expression between day 3 and baseline. Secondary outcomes compared the groups on the mean or median change in CD11b expression, neutrophil chemotaxis, presepsin, cardiovascular Sequential Organ Failure Assessment (CVS SOFA) score, vasopressor dose, and EAA level between day 3 and baseline. We further compared the groups on mortality, ICU-free days, ventilator-free days, dialysis dependence status, renal recovery, serum creatinine, vasopressor-free days, and major adverse kidney events (MAKE 28), measured on day 28.

RESULTS: Fifty-nine patients were randomized to PMX-HP (n = 29) and non-PMX-HP (n = 30) groups. At baseline, mHLA-DR expression, CD11b, neutrophil chemotaxis, and clinical parameters were comparable between groups. The median change in mHLA-DR expression between day 3 and baseline was higher in PMX-HP patients than in patients receiving standard therapy alone (P = 0.027). The mean change in CD11b between day 3 and baseline was significantly lower in the PMX-HP group than in the non-PMX-HP group (P = 0.002). There were no significant changes from baseline in neutrophil chemotaxis, presepsin, CVS SOFA scores, vasopressor doses, or EAA level between groups. On day 28 after enrollment, mortality, ICU-free days, ventilator-free days, dialysis dependence status, renal recovery, serum creatinine, vasopressor-free days, and MAKE 28 were comparable between groups.

CONCLUSION: PMX-HP improved mHLA-DR expression in severe sepsis patients. Future studies should examine the potential benefit of PMX-HP in patients with low mHLA-DR expression.

TRIAL REGISTRATION: ClinicalTrials.gov, NCT02413541 . Registered on 3 March 2015.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Srisawat N, Tungsanga S, Lumlertgul N, et al. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Crit Care. 2018. PMID: 30367647. doi:10.1186/s13054-018-2077-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。